Literature DB >> 24976707

Human genes involved in hepatitis B virus infection.

Zheng Zeng1.   

Abstract

Persistent hepatitis B virus (HBV) infection is a significant public health problem because it is a major cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC). Roughly one-third of the world population has been infected with HBV and there are about 350 million (5%-6%) persistent carriers. HBV causes 80% of all liver cancer cases and is the second most important carcinogen, after smoking tobacco. There is an approximate 90% risk of becoming a persistent carrier following perinatal infection in infants born to e antigen positive carrier mothers and a 30% risk in pre-school children. Only 5%-10% of adults become persistent carriers following infection. Of individuals persistently infected with HBV, 10%-30% will develop liver cirrhosis and HCC. These highly variable outcomes in both clearance rates and disease outcomes in persistently infected individuals cannot be fully explained by differences in immunological, viral or environmental factors. Thus, differences in host genetic factors may affect the natural history of hepatitis B.

Entities:  

Keywords:  Clearance; Epidemiology; Genetic; Hepatitis B virus; Hepatocellular carcinoma; Natural history; Outcome; Persistance; Polymorphism

Mesh:

Substances:

Year:  2014        PMID: 24976707      PMCID: PMC4069298          DOI: 10.3748/wjg.v20.i24.7696

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  86 in total

1.  Human T cell leukemia virus type I (HTLV-I)-specific CD8+ CTL clones from patients with HTLV-I-associated neurologic disease secrete proinflammatory cytokines, chemokines, and matrix metalloproteinase.

Authors:  W E Biddison; R Kubota; T Kawanishi; D D Taub; W W Cruikshank; D M Center; E W Connor; U Utz; S Jacobson
Journal:  J Immunol       Date:  1997-08-15       Impact factor: 5.422

2.  A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population.

Authors:  Hamdi Mbarek; Hidenori Ochi; Yuji Urabe; Vinod Kumar; Michiaki Kubo; Naoya Hosono; Atsushi Takahashi; Yoichiro Kamatani; Daiki Miki; Hiromi Abe; Tatsuhiko Tsunoda; Naoyuki Kamatani; Kazuaki Chayama; Yusuke Nakamura; Koichi Matsuda
Journal:  Hum Mol Genet       Date:  2011-07-12       Impact factor: 6.150

3.  Chronic liver disease in central Harlem: the role of alcohol and viral hepatitis.

Authors:  T R Frieden; L Ozick; C McCord; O V Nainan; S Workman; G Comer; T P Lee; K S Byun; D Patel; K J Henning
Journal:  Hepatology       Date:  1999-03       Impact factor: 17.425

4.  Beta-chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans.

Authors:  L Wagner; O O Yang; E A Garcia-Zepeda; Y Ge; S A Kalams; B D Walker; M S Pasternack; A D Luster
Journal:  Nature       Date:  1998-02-26       Impact factor: 49.962

5.  The tumour necrosis factor-α-238A allele increases the risk of chronic HBV infection in European populations.

Authors:  M-H Zheng; D-D Xiao; X-F Lin; S-J Wu; M-M Peng; X-Y Yu; W-Y Liu; L-F Li; K-Q Shi; Y-C Fan; Y-P Chen
Journal:  J Viral Hepat       Date:  2011-07-22       Impact factor: 3.728

6.  Tumour necrosis factor-α-857T allele reduces the risk of hepatitis B virus infection in an Asian population.

Authors:  K-Q Shi; X-H Cai; D-D Xiao; S-J Wu; M-M Peng; X-F Lin; W-Y Liu; Y-C Fan; Y-P Chen; M-H Zheng
Journal:  J Viral Hepat       Date:  2011-11-17       Impact factor: 3.728

7.  A common HLA-DPA1 variant is a major determinant of hepatitis B virus clearance in Han Chinese.

Authors:  Ping An; Cheryl Winkler; Li Guan; Stephen J O'Brien; Zheng Zeng
Journal:  J Infect Dis       Date:  2011-04-01       Impact factor: 5.226

8.  Polymorphisms near interleukin 28B gene are not associated with hepatitis B virus clearance, hepatitis B e antigen clearance and hepatocellular carcinoma occurrence.

Authors:  Dong Hyeon Lee; Yuri Cho; Ji Yeon Seo; Jung Hee Kwon; Eun Ju Cho; Eun Sun Jang; Min-Sun Kwak; Jae Youn Cheong; Sung Won Cho; Jeong-Hoon Lee; Su Jong Yu; Jung-Hwan Yoon; Hyo-Suk Lee; Chung Yong Kim; Hyoung Doo Shin; Yoon Jun Kim
Journal:  Intervirology       Date:  2013-01-22       Impact factor: 1.763

9.  Role of HLA-DP polymorphisms on chronicity and disease activity of hepatitis B infection in Southern Chinese.

Authors:  Danny Ka-Ho Wong; Tsunamasa Watanabe; Yasuhito Tanaka; Wai-Kay Seto; Cheuk-Kwong Lee; James Fung; Che-Kit Lin; Fung-Yu Huang; Ching-Lung Lai; Man-Fung Yuen
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

10.  An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles.

Authors:  A G Wilson; N de Vries; F Pociot; F S di Giovine; L B van der Putte; G W Duff
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

View more
  18 in total

1.  New Gene Variants Associated with the Risk of Chronic HBV Infection.

Authors:  Mengjie Fan; Jing Wang; Sa Wang; Tengyan Li; Hong Pan; Hankui Liu; Huifang Xu; Daria V Zhernakova; Stephen J O'Brien; Zhenru Feng; Le Chang; Erhei Dai; Jianhua Lu; Hongli Xi; Yanyan Yu; Jianguo Zhang; Binbin Wang; Zheng Zeng
Journal:  Virol Sin       Date:  2020-04-15       Impact factor: 4.327

2.  Interleukin-6 gene variants are associated with reduced risk of chronicity in hepatitis B virus infection in a Malaysian population.

Authors:  Behnaz Riazalhosseini; Zahurin Mohamed; Yamunah Devi Apalasamy; Noor Shafila Shafie; Rosmawati Mohamed
Journal:  Biomed Rep       Date:  2018-07-09

3.  Identified OAS3 gene variants associated with coexistence of HBsAg and anti-HBs in chronic HBV infection.

Authors:  S Wang; J Wang; M-J Fan; T-Y Li; H Pan; X Wang; H-K Liu; Q-F Lin; J-G Zhang; L-P Guan; D V Zhernakova; S J O'Brien; Z-R Feng; L Chang; E-H Dai; J-H Lu; H-L Xi; Z Zeng; Y-Y Yu; B-B Wang
Journal:  J Viral Hepat       Date:  2018-05-29       Impact factor: 3.728

Review 4.  Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma.

Authors:  Vikrant Rai; Joe Abdo; Abdullah N Alsuwaidan; Swati Agrawal; Poonam Sharma; Devendra K Agrawal
Journal:  Mol Cell Biochem       Date:  2017-06-07       Impact factor: 3.842

5.  MicroRNA-495 suppresses cell proliferation and invasion of hepatocellular carcinoma by directly targeting insulin-like growth factor receptor-1.

Authors:  Ying Ye; Juhua Zhuang; Guangdong Wang; Saifei He; Suiliang Zhang; Guoyu Wang; Jing Ni; Jiening Wang; Wei Xia
Journal:  Exp Ther Med       Date:  2017-11-08       Impact factor: 2.751

6.  Genomics and infectious disease: a call to identify the ethical, legal and social implications for public health and clinical practice.

Authors:  Gail Geller; Rachel Dvoskin; Chloe L Thio; Priya Duggal; Michelle H Lewis; Theodore C Bailey; Andrea Sutherland; Daniel A Salmon; Jeffrey P Kahn
Journal:  Genome Med       Date:  2014-11-18       Impact factor: 11.117

7.  Role of IL-4 gene polymorphisms in HBV-related hepatocellular carcinoma in a Chinese population.

Authors:  Yu Lu; Zhitong Wu; Qiliu Peng; Liping Ma; Xiaolian Zhang; Jiangyang Zhao; Xue Qin; Shan Li
Journal:  PLoS One       Date:  2014-10-08       Impact factor: 3.240

8.  Host Genetic Variants in HLA Loci Influence Risk for Hepatitis B Virus Infection in Children.

Authors:  Jie Fan; Xin Huang; Juan Chen; Yiling Cai; Lin Xiong; Lihong Mu; Li Zhou
Journal:  Hepat Mon       Date:  2016-07-24       Impact factor: 0.660

9.  Association between IL-18 polymorphisms, serum levels, and HBV-related hepatocellular carcinoma in a Chinese population: a retrospective case-control study.

Authors:  Jingui Bao; Yu Lu; Yan Deng; Chengzhi Rong; Yanqiong Liu; Xiuli Huang; Liuying Song; Shan Li; Xue Qin
Journal:  Cancer Cell Int       Date:  2015-07-25       Impact factor: 5.722

10.  Association of Ghrelin Gene Polymorphisms and Serum Ghrelin Levels with the Risk of Hepatitis B Virus-Related Liver Diseases in a Chinese Population.

Authors:  Xiaolian Zhang; Limin Zhai; Chengzhi Rong; Xue Qin; Shan Li
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.